Antonios Aliprantis

Antonios (Tony) Aliprantis joined Flagship Pioneering in 2021. As Chief Medical Officer for Pioneering Medicines, Tony is the leadership point of contact for all clinical development activities at Pioneering Medicines as their pipeline expands to the clinic. Previously at Flagship, Tony led drug R&D programs, including the discovery of a long-acting TSLP antibody in collaboration with Generate Biomedicines, and established Project Leadership capabilities at Pioneering Medicines.

Previously, Tony was the Vaccines Therapeutic Area Lead in the Translational Pharmacology group at Merck, where he oversaw a portfolio of early vaccine programs, including two mRNA vaccines and a monoclonal antibody to protect against a respiratory viral infection, and provided clinical pharmacology support for the successful filing of a small molecule therapy for heart failure. Prior to Merck, Tony was a faculty member at Brigham and Women’s Hospital and Harvard Medical School, where he ran an NIH-funded laboratory investigating bone biology, inflammation, arthritis, and fibrosis, and oversaw the Osteoarthritis Center, which provided clinical care and conducted translational research.

Tony has co-authored over 45 publications and made contributions to articles published in Science, Proceedings of the National Academy of Sciences, and The Journal of Clinical Investigation. He received his M.D. and Ph.D. from NYU School of Medicine and his B.A. in Biochemistry from New York University.